A randomized crossover study to compare efavirenz and etravirine treatment
Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavourable blood lipid profile. We investigated the effect of replacing EFV with etravirine (ETR) on patient preference, sleep, anxiety and lipid levels. Study participants did not complain of side-effects, had tolerated EFV for at least...
Uloženo v:
| Vydáno v: | AIDS (London) Ročník 25; číslo 1; s. 57 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
02.01.2011
|
| Témata: | |
| ISSN: | 1473-5571, 1473-5571 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavourable blood lipid profile. We investigated the effect of replacing EFV with etravirine (ETR) on patient preference, sleep, anxiety and lipid levels.
Study participants did not complain of side-effects, had tolerated EFV for at least 3 months, with less than 50 copies/ml HIV-RNA. After randomization, the ETR-first group started with ETR (400 mg daily) [DOSAGE ERROR CORRECTED] with EFV-placebo and the EFV-first group with EFV with ETR-placebo. After 6 weeks, both groups switched to the alternate regimen. Nucleoside reverse transcriptase inhibitors were continued without any change. The primary end point was patient preference for the first or the second regimen, assessed after 12 weeks.
Fifty-eight patients were enrolled with a median CD4 cell count of 589 cells/μl and the duration of previous EFV therapy was 3.9 years. Fifty-five patients completed the study. When asked about treatment preference after 12 weeks, 16 preferred EFV and 22 preferred ETR, whereas 17 did not express a preference (P = NS). Patients who continued EFV during the first phase of the trial preferred EFV (15/21, 71%), whereas patients who started with ETR were more likely to prefer ETR (n = 16/17, 94%). This order effect was strongly significant (P < 0.0001). Quality of sleep, depression, anxiety and stress scores did not differ significantly between groups. Median plasma cholesterol levels decreased by 0.7 mmol (29 mg/100 ml) after replacing EFV with ETR (P < 0.002).
After substitution of EFV by ETR, patients did not express a significant preference for ETR. There was no measurable effect on neuropsychiatric symptoms and sleep. Cholesterol decreased. |
|---|---|
| AbstractList | Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavourable blood lipid profile. We investigated the effect of replacing EFV with etravirine (ETR) on patient preference, sleep, anxiety and lipid levels.BACKGROUNDEfavirenz (EFV) causes neuropsychiatric side-effects and an unfavourable blood lipid profile. We investigated the effect of replacing EFV with etravirine (ETR) on patient preference, sleep, anxiety and lipid levels.Study participants did not complain of side-effects, had tolerated EFV for at least 3 months, with less than 50 copies/ml HIV-RNA. After randomization, the ETR-first group started with ETR (400 mg daily) [DOSAGE ERROR CORRECTED] with EFV-placebo and the EFV-first group with EFV with ETR-placebo. After 6 weeks, both groups switched to the alternate regimen. Nucleoside reverse transcriptase inhibitors were continued without any change. The primary end point was patient preference for the first or the second regimen, assessed after 12 weeks.METHODStudy participants did not complain of side-effects, had tolerated EFV for at least 3 months, with less than 50 copies/ml HIV-RNA. After randomization, the ETR-first group started with ETR (400 mg daily) [DOSAGE ERROR CORRECTED] with EFV-placebo and the EFV-first group with EFV with ETR-placebo. After 6 weeks, both groups switched to the alternate regimen. Nucleoside reverse transcriptase inhibitors were continued without any change. The primary end point was patient preference for the first or the second regimen, assessed after 12 weeks.Fifty-eight patients were enrolled with a median CD4 cell count of 589 cells/μl and the duration of previous EFV therapy was 3.9 years. Fifty-five patients completed the study. When asked about treatment preference after 12 weeks, 16 preferred EFV and 22 preferred ETR, whereas 17 did not express a preference (P = NS). Patients who continued EFV during the first phase of the trial preferred EFV (15/21, 71%), whereas patients who started with ETR were more likely to prefer ETR (n = 16/17, 94%). This order effect was strongly significant (P < 0.0001). Quality of sleep, depression, anxiety and stress scores did not differ significantly between groups. Median plasma cholesterol levels decreased by 0.7 mmol (29 mg/100 ml) after replacing EFV with ETR (P < 0.002).RESULTSFifty-eight patients were enrolled with a median CD4 cell count of 589 cells/μl and the duration of previous EFV therapy was 3.9 years. Fifty-five patients completed the study. When asked about treatment preference after 12 weeks, 16 preferred EFV and 22 preferred ETR, whereas 17 did not express a preference (P = NS). Patients who continued EFV during the first phase of the trial preferred EFV (15/21, 71%), whereas patients who started with ETR were more likely to prefer ETR (n = 16/17, 94%). This order effect was strongly significant (P < 0.0001). Quality of sleep, depression, anxiety and stress scores did not differ significantly between groups. Median plasma cholesterol levels decreased by 0.7 mmol (29 mg/100 ml) after replacing EFV with ETR (P < 0.002).After substitution of EFV by ETR, patients did not express a significant preference for ETR. There was no measurable effect on neuropsychiatric symptoms and sleep. Cholesterol decreased.CONCLUSIONAfter substitution of EFV by ETR, patients did not express a significant preference for ETR. There was no measurable effect on neuropsychiatric symptoms and sleep. Cholesterol decreased. Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavourable blood lipid profile. We investigated the effect of replacing EFV with etravirine (ETR) on patient preference, sleep, anxiety and lipid levels. Study participants did not complain of side-effects, had tolerated EFV for at least 3 months, with less than 50 copies/ml HIV-RNA. After randomization, the ETR-first group started with ETR (400 mg daily) [DOSAGE ERROR CORRECTED] with EFV-placebo and the EFV-first group with EFV with ETR-placebo. After 6 weeks, both groups switched to the alternate regimen. Nucleoside reverse transcriptase inhibitors were continued without any change. The primary end point was patient preference for the first or the second regimen, assessed after 12 weeks. Fifty-eight patients were enrolled with a median CD4 cell count of 589 cells/μl and the duration of previous EFV therapy was 3.9 years. Fifty-five patients completed the study. When asked about treatment preference after 12 weeks, 16 preferred EFV and 22 preferred ETR, whereas 17 did not express a preference (P = NS). Patients who continued EFV during the first phase of the trial preferred EFV (15/21, 71%), whereas patients who started with ETR were more likely to prefer ETR (n = 16/17, 94%). This order effect was strongly significant (P < 0.0001). Quality of sleep, depression, anxiety and stress scores did not differ significantly between groups. Median plasma cholesterol levels decreased by 0.7 mmol (29 mg/100 ml) after replacing EFV with ETR (P < 0.002). After substitution of EFV by ETR, patients did not express a significant preference for ETR. There was no measurable effect on neuropsychiatric symptoms and sleep. Cholesterol decreased. |
| Author | Elzi, Luigia Mercier, Isabelle K Genné, Daniel Nguyen, Alain Fayet-Mello, Aurélie Hirschel, Bernard Calmy, Alexandra Rauch, Andri Cavassini, Matthias Bernasconi, Enos Delhumeau, Cécile |
| Author_xml | – sequence: 1 givenname: Alain surname: Nguyen fullname: Nguyen, Alain organization: University Clinic of Infectious Diseases, University Hospital of Geneva, Switzerland – sequence: 2 givenname: Alexandra surname: Calmy fullname: Calmy, Alexandra – sequence: 3 givenname: Cécile surname: Delhumeau fullname: Delhumeau, Cécile – sequence: 4 givenname: Isabelle K surname: Mercier fullname: Mercier, Isabelle K – sequence: 5 givenname: Matthias surname: Cavassini fullname: Cavassini, Matthias – sequence: 6 givenname: Aurélie surname: Fayet-Mello fullname: Fayet-Mello, Aurélie – sequence: 7 givenname: Luigia surname: Elzi fullname: Elzi, Luigia – sequence: 8 givenname: Daniel surname: Genné fullname: Genné, Daniel – sequence: 9 givenname: Andri surname: Rauch fullname: Rauch, Andri – sequence: 10 givenname: Enos surname: Bernasconi fullname: Bernasconi, Enos – sequence: 11 givenname: Bernard surname: Hirschel fullname: Hirschel, Bernard |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21076278$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLAzEYRYNU7EP_gUh2rqbmMZlJlqXWFwURdD3k8QVGOpOaZArtr7diBVf3XDhcuFM06kMPCF1TMqdE1Xdvi_s5MYRy4Exy7pWv-Bma0LLmhRA1Hf3jMZqm9EkIEUTKCzRmlNQVq-UEvSxw1L0LXXsAh20MKYUdRJzy4PY4B2xDt9URMHi9ayP0B3zUMeT4U9secI6gcwd9vkTnXm8SXJ1yhj4eVu_Lp2L9-vi8XKwLyyuZC2WEqagDMIJSVjplnFPOMS-0kUwrK43TyigBtLQ1cUoYEMQyrr0n9AgzdPu7u43ha4CUm65NFjYb3UMYUiOpLAkvlTiaNydzMB24ZhvbTsd983effQOoT2G8 |
| CitedBy_id | crossref_primary_10_3109_00365548_2013_773067 crossref_primary_10_1111_eci_12464 crossref_primary_10_1097_JNC_0000000000000326 crossref_primary_10_1586_eri_11_125 crossref_primary_10_1007_s40265_015_0515_6 crossref_primary_10_1097_QAI_0b013e31829d63ab crossref_primary_10_1097_QAD_0000000000002206 crossref_primary_10_1097_QAD_0b013e328348dab0 crossref_primary_10_1177_2050312116686482 crossref_primary_10_1111_hiv_13526 crossref_primary_10_1155_2014_636584 crossref_primary_10_1186_s12981_020_00303_1 crossref_primary_10_3810_pgm_2012_01_2515 crossref_primary_10_1097_QAD_0b013e328353b047 crossref_primary_10_1080_09540121_2013_841825 crossref_primary_10_1186_s12886_020_01616_5 crossref_primary_10_1371_journal_pone_0084676 crossref_primary_10_1080_14740338_2016_1206076 crossref_primary_10_2147_NSS_S377464 crossref_primary_10_3109_23744235_2015_1133927 crossref_primary_10_1124_mol_115_098590 crossref_primary_10_1080_09540121_2023_2275035 crossref_primary_10_1586_14787210_2014_944506 crossref_primary_10_1111_jsr_12196 crossref_primary_10_1186_1477_7525_11_164 crossref_primary_10_1097_QAD_0b013e32834c4c06 crossref_primary_10_1111_hiv_12426 crossref_primary_10_1093_cid_cis192 crossref_primary_10_1097_QAI_0000000000003468 crossref_primary_10_1111_hiv_12104 crossref_primary_10_1371_journal_pone_0073398 |
| ContentType | Journal Article |
| Contributor | Bucher, H C Weber, R Rickenbach, M Furrer, H Schüpbach, J Trkola, A Regenass, S Flepp, M Klimkait, T Cavassini, M Francioli, P Ledergerber, B Schultze, D Calmy, A Egger, M Elzi, L Hösli, I Pantaleo, G Rauch, A Günthard, H Kovari, H Böni, J Kaiser, L Bürgisser, P Barth, J Rudin, C Müller, N Dubs, R Fehr, J Martinez de Tejada, B Schöni-Affolter, F Keiser, O Battegay, M Fischer, M Kind, C Vernazza, P Burton-Jeangros, C Schmid, P Bernasconi, E Hasse, B Taffé, P Speck, R Hirsch, H H Kahlert, C Telenti, A Fux, C A Martinetti, G Nadal, D Hirschel, B von Wyl, V Yerly, S Gorgievski, M |
| Contributor_xml | – sequence: 1 givenname: J surname: Barth fullname: Barth, J – sequence: 2 givenname: M surname: Battegay fullname: Battegay, M – sequence: 3 givenname: E surname: Bernasconi fullname: Bernasconi, E – sequence: 4 givenname: J surname: Böni fullname: Böni, J – sequence: 5 givenname: H C surname: Bucher fullname: Bucher, H C – sequence: 6 givenname: P surname: Bürgisser fullname: Bürgisser, P – sequence: 7 givenname: C surname: Burton-Jeangros fullname: Burton-Jeangros, C – sequence: 8 givenname: A surname: Calmy fullname: Calmy, A – sequence: 9 givenname: M surname: Cavassini fullname: Cavassini, M – sequence: 10 givenname: R surname: Dubs fullname: Dubs, R – sequence: 11 givenname: M surname: Egger fullname: Egger, M – sequence: 12 givenname: L surname: Elzi fullname: Elzi, L – sequence: 13 givenname: J surname: Fehr fullname: Fehr, J – sequence: 14 givenname: M surname: Fischer fullname: Fischer, M – sequence: 15 givenname: M surname: Flepp fullname: Flepp, M – sequence: 16 givenname: P surname: Francioli fullname: Francioli, P – sequence: 17 givenname: H surname: Furrer fullname: Furrer, H – sequence: 18 givenname: C A surname: Fux fullname: Fux, C A – sequence: 19 givenname: M surname: Gorgievski fullname: Gorgievski, M – sequence: 20 givenname: H surname: Günthard fullname: Günthard, H – sequence: 21 givenname: B surname: Hasse fullname: Hasse, B – sequence: 22 givenname: H H surname: Hirsch fullname: Hirsch, H H – sequence: 23 givenname: B surname: Hirschel fullname: Hirschel, B – sequence: 24 givenname: I surname: Hösli fullname: Hösli, I – sequence: 25 givenname: C surname: Kahlert fullname: Kahlert, C – sequence: 26 givenname: L surname: Kaiser fullname: Kaiser, L – sequence: 27 givenname: O surname: Keiser fullname: Keiser, O – sequence: 28 givenname: C surname: Kind fullname: Kind, C – sequence: 29 givenname: T surname: Klimkait fullname: Klimkait, T – sequence: 30 givenname: H surname: Kovari fullname: Kovari, H – sequence: 31 givenname: B surname: Ledergerber fullname: Ledergerber, B – sequence: 32 givenname: G surname: Martinetti fullname: Martinetti, G – sequence: 33 givenname: B surname: Martinez de Tejada fullname: Martinez de Tejada, B – sequence: 34 givenname: N surname: Müller fullname: Müller, N – sequence: 35 givenname: D surname: Nadal fullname: Nadal, D – sequence: 36 givenname: G surname: Pantaleo fullname: Pantaleo, G – sequence: 37 givenname: A surname: Rauch fullname: Rauch, A – sequence: 38 givenname: S surname: Regenass fullname: Regenass, S – sequence: 39 givenname: M surname: Rickenbach fullname: Rickenbach, M – sequence: 40 givenname: C surname: Rudin fullname: Rudin, C – sequence: 41 givenname: P surname: Schmid fullname: Schmid, P – sequence: 42 givenname: D surname: Schultze fullname: Schultze, D – sequence: 43 givenname: F surname: Schöni-Affolter fullname: Schöni-Affolter, F – sequence: 44 givenname: J surname: Schüpbach fullname: Schüpbach, J – sequence: 45 givenname: R surname: Speck fullname: Speck, R – sequence: 46 givenname: P surname: Taffé fullname: Taffé, P – sequence: 47 givenname: A surname: Telenti fullname: Telenti, A – sequence: 48 givenname: A surname: Trkola fullname: Trkola, A – sequence: 49 givenname: P surname: Vernazza fullname: Vernazza, P – sequence: 50 givenname: V surname: von Wyl fullname: von Wyl, V – sequence: 51 givenname: R surname: Weber fullname: Weber, R – sequence: 52 givenname: S surname: Yerly fullname: Yerly, S |
| CorporateAuthor | Swiss HIV Cohort Study |
| CorporateAuthor_xml | – name: Swiss HIV Cohort Study |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/QAD.0b013e32833f9f63 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-5571 |
| ExternalDocumentID | 21076278 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .XZ .Z2 01R 0R~ 1J1 23M 2WC 354 40H 4Q1 4Q2 4Q3 5GY 5RE 5VS 71W 77Y 7O~ 85S 8L- AAAAV AAAXR AAGIX AAIQE AAJCS AAMOA AAMTA AARTV AASOK AAUEB AAXQO ABBUW ABDIG ABIVO ABJNI ABPXF ABXVJ ABZAD ACCJW ACDDN ACDOF ACEWG ACGFS ACILI ACOAL ACWDW ACWRI ACXNZ ACZKN ADBBV ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFEXH AFNMH AFUWQ AGINI AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMNEI BAWUL BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIK DIWNM DUNZO E.X E3Z EBS ECM EIF EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 H0~ HZ~ IKREB IKYAY IN~ JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B O9- OAG OAH OBH ODMTH OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OPX OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P2P RLZ S4R S4S SJN TEORI TR2 V2I VVN W3M WOQ WOW X3V X3W XJT XXN XYM YFH ZZMQN 7X8 ADKSD |
| ID | FETCH-LOGICAL-c368t-9b5b61deeb51124d9bdd9dd2f5ab82a9c8bda9b95e14c70d95be50c23aff010c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 36 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000284823900007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1473-5571 |
| IngestDate | Sun Sep 28 08:24:27 EDT 2025 Mon Jul 21 05:54:36 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c368t-9b5b61deeb51124d9bdd9dd2f5ab82a9c8bda9b95e14c70d95be50c23aff010c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 21076278 |
| PQID | 818403495 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_818403495 pubmed_primary_21076278 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-01-02 |
| PublicationDateYYYYMMDD | 2011-01-02 |
| PublicationDate_xml | – month: 01 year: 2011 text: 2011-01-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | AIDS (London) |
| PublicationTitleAlternate | AIDS |
| PublicationYear | 2011 |
| References | AIDS. 2011 Mar 13;25(5):729 |
| References_xml | – reference: - AIDS. 2011 Mar 13;25(5):729 |
| SSID | ssj0005088 |
| Score | 2.200155 |
| Snippet | Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavourable blood lipid profile. We investigated the effect of replacing EFV with etravirine (ETR)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 57 |
| SubjectTerms | Adult Antiretroviral Therapy, Highly Active Anxiety Disorders - chemically induced Anxiety Disorders - psychology Benzoxazines - adverse effects Benzoxazines - therapeutic use CD4 Lymphocyte Count Drug Administration Schedule Female HIV Infections - drug therapy HIV Infections - psychology HIV Protease Inhibitors - adverse effects HIV Protease Inhibitors - therapeutic use HIV-1 Humans Male Middle Aged Practice Guidelines as Topic Pyridazines - administration & dosage Pyridazines - adverse effects Pyridazines - therapeutic use Sleep Initiation and Maintenance Disorders - chemically induced Sleep Initiation and Maintenance Disorders - psychology Surveys and Questionnaires Treatment Outcome |
| Title | A randomized crossover study to compare efavirenz and etravirine treatment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21076278 https://www.proquest.com/docview/818403495 |
| Volume | 25 |
| WOSCitedRecordID | wos000284823900007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7Uinjx_agv9uB1aZvNNrsnKWoRoaWCQm9hn-DBpLaxh_56Z_OoJ_EghEAgCWF2Mt83j50BuEUMNghUhgrpNY37PUWl1Jra2Ok48ohKypbDJpLxWEynclLX5izqssrGJpaG2uYmxMg7IrgiDOn83eyThqFRIblaT9DYhBZDJhOUOpn-NAsP3KPcXJQwynnSa3bOyaTzMnhoQoCIr8xLH_qA_sYxS6wZ7v_zKw9gryaZZFBpxSFsuOwIdkZ1Gv0YngcEIcrmH-8rZ0kJlKGSk5S9ZkmRk7oynTivlmgTsxXB24kr5uESX0HW9ekn8DZ8fL1_ovVQBWpYXxRUaq77PeucDlQrtlJbK62NPFdaREoaoa2SWnIXVrFrJdeOd03ElPfou5noFLayPHPnQFjsFDIQoboKTUEUK4nyTLzisfIKpd4G0ggpRaUNmQiVufxrka7F1IazStDprGqukaILivY5ERd_P3wJu1WEF4_oCloef1h3DdtmWbwv5jelMuB5PBl9A98rwCE |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized+crossover+study+to+compare+efavirenz+and+etravirine+treatment&rft.jtitle=AIDS+%28London%29&rft.au=Nguyen%2C+Alain&rft.au=Calmy%2C+Alexandra&rft.au=Delhumeau%2C+C%C3%A9cile&rft.au=Mercier%2C+Isabelle+K&rft.date=2011-01-02&rft.eissn=1473-5571&rft.volume=25&rft.issue=1&rft.spage=57&rft_id=info:doi/10.1097%2FQAD.0b013e32833f9f63&rft_id=info%3Apmid%2F21076278&rft_id=info%3Apmid%2F21076278&rft.externalDocID=21076278 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-5571&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-5571&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-5571&client=summon |